title: [Novel approved form of treatment for colonic cancer with peritoneal metastases - radicality-aimed surgery combined with hyperthermic intraperitoneal chemotherapy].
abstract: Carcinomatosis occurs in almost 10% of colonic cancer patients, whereby the five-year survival rate on cytostatic chemotherapy is approx. 13% at best. For patients having carcinomatosis restricted to a fairly small area, surgical removal of peritoneal metastases combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may be a curative procedure. The treatment has resulted in a five-year life expectancy of 30 to 35% for selected patients. The treatment is, however, associated with significant morbidity and even mortality. Colorectal cancer patients diagnosed with restricted peritoneal carcinomatosis should be referred to an assessment for HPEC treatment.
authors.forename: Anna
authors.initials: A
authors.lastname: Lepistö
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion; D003110:Colonic Neoplasms / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D010534:Peritoneal Neoplasms / Q000556:secondary* / Q000628:therapy*; D016019:Survival Analysis